Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Mol Oncol. 2013 Aug;7(4):826-39. doi: 10.1016/j.molonc.2013.04.002. Epub 2013 Apr 18.
The cancer invasion front (CIF), a spatially-recognized area due to the frequent presence of peritumoral desmoplastic reaction, represents a cancer site where many hallmarks of cancer metastasis occur. It is now strongly suggested that the desmoplastic microenvironment holds crucial information for determining tumor development and progression. Despite extensive research on tumor-host cell interactions at CIFs, the exact paracrine molecular network that is hardwired into the proteome of the stromal and cancer subpopulations remains partially understood. Here, we interrogated the signaling pathways and the molecular functional signatures across the proteome of a desmoplastic coculture model system of colorectal cancer progression. We discovered a group of bone morphogenetic protein (BMP) antagonists that coordinates major biological programs in CIFs, including cell proliferation, invasion, migration and differentiation processes. Using a mathematical model of cancer cell progression, coupled to in vitro cell migration assays, we demonstrated that the prominent BMP antagonist gremlin-1 (GREM1) may trigger motility of cancer cell cohorts. Our data collectively demonstrate that the desmoplastic CIFs deploy a microenvironmental signature, based on BMP antagonism, in order to regulate the motogenic fates of cancer cell cohorts invading the adjacent stroma.
癌症侵袭前沿(CIF),由于经常存在肿瘤周围的促结缔组织反应,是一个空间上可识别的区域,代表了癌症发生的部位,许多癌症转移的特征都在此出现。现在强烈表明,促结缔组织反应的微环境为确定肿瘤的发展和进展提供了关键信息。尽管在 CIF 处对肿瘤-宿主细胞相互作用进行了广泛的研究,但对于编入基质和癌症亚群蛋白质组的旁分泌分子网络的确切机制仍部分了解。在这里,我们研究了在结直肠癌细胞进展的促结缔组织反应共培养模型系统的蛋白质组中的信号通路和分子功能特征。我们发现了一组骨形态发生蛋白(BMP)拮抗剂,它们协调 CIF 中的主要生物学程序,包括细胞增殖、侵袭、迁移和分化过程。使用癌症细胞进展的数学模型,结合体外细胞迁移测定,我们证明了突出的 BMP 拮抗剂骨形态发生蛋白抑制剂 1(GREM1)可能触发癌症细胞群的迁移。我们的数据共同表明,促结缔组织反应的 CIF 部署了基于 BMP 拮抗作用的微环境特征,以调节侵袭相邻基质的癌症细胞群的运动命运。
Breast Cancer Res. 2019-9-18
Front Immunol. 2025-2-24
Front Pharmacol. 2024-6-12
Int J Mol Sci. 2022-10-20
Front Cell Dev Biol. 2022-1-20
BMC Cardiovasc Disord. 2013-1-16
Oncogene. 2012-10-22
Angiogenesis. 2012-9-30
Mod Pathol. 2012-7-13
Methods Mol Biol. 2011
Proc Natl Acad Sci U S A. 2011-4-7